Brentuximab vedotin monotherapy is an effective treatment in a frail pediatric patient with Down syndrome and classical Hodgkin lymphoma

Pediatr Blood Cancer. 2020 Feb;67(2):e28082. doi: 10.1002/pbc.28082. Epub 2019 Nov 14.

Authors

Julia Vonasek¹, Pernille Wendtland Edslev¹, Francesco d'Amore², Henrik Hasle¹

Affiliations

¹ Department of Pediatric and Adolescent Health, Aarhus University Hospital, Aarhus, Denmark.
² Department of Hematology, Aarhus University Hospital, Aarhus, Denmark.

PMID: 31724794
DOI: 10.1002/pbc.28082

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adolescent
Antineoplastic Agents, Immunological / therapeutic use*
Brentuximab Vedotin / therapeutic use*
Down Syndrome / complications
Down Syndrome / drug therapy*
Down Syndrome / pathology
Female
Hodgkin Disease / complications
Hodgkin Disease / drug therapy*
Hodgkin Disease / pathology
Humans
Remission Induction
Treatment Outcome

Substances

Antineoplastic Agents, Immunological
Brentuximab Vedotin